U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H18ClN3O4S2
Molecular Weight 379.883
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CYCLOPENTHIAZIDE

SMILES

NS(=O)(=O)C1=C(Cl)C=C2NC(CC3CCCC3)NS(=O)(=O)C2=C1

InChI

InChIKey=BKYKPTRYDKTTJY-UHFFFAOYSA-N
InChI=1S/C13H18ClN3O4S2/c14-9-6-10-12(7-11(9)22(15,18)19)23(20,21)17-13(16-10)5-8-3-1-2-4-8/h6-8,13,16-17H,1-5H2,(H2,15,18,19)

HIDE SMILES / InChI

Description

Cyclopenthiazide is a thiazide diuretic. It inhibits the Na+-Cl− symporter in the distal convoluted tubule of the kidney. Cyclopenthiazide is used for the treatment of edema, including that associated with heart failure, and for the treatment of hypertension.

Approval Year

Unknown
139,594

Targets

Primary TargetPharmacologyConditionPotency
Solute carrier family 12 member 3
3
Inhibitor
8,297

Conditions

ConditionModalityTargetsHighest PhaseProduct
Hypertension
567
 Primary
Approved
8,429
NAVIDREX
Edema
22
 Primary
Approved
8,429
NAVIDREX
Heart failure
103
 Primary
Approved
8,429
NAVIDREX

PubMed

Sample Use Guides

In Vivo Use Guide
The usual adult dose is half of one tablet (0.25 mg) , or one whole tablet (0.5 mg) a day, alone or with other medicines.
Route of Administration: Oral
In Vitro Use Guide
Unknown
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966